Pfiz­er plans to study a third shot for its Covid-19 vac­cine in the youngest kids, push­ing back its time­line far­ther

Amer­i­can chil­dren un­der the age of five may not be vac­ci­nat­ed un­til mid-2022, as Pfiz­er said Fri­day that it’s go­ing to now test a third dose of its Covid-19 vac­cine in the tri­al.

The de­ci­sion comes as Pfiz­er an­nounced non-in­fe­ri­or­i­ty was not met for chil­dren be­tween the ages of two and five when com­pared to old­er teenagers in the cur­rent tri­al.

Pfiz­er pre­vi­ous­ly said it might ap­ply for an EUA in this youngest pop­u­la­tion by the end of De­cem­ber or ear­ly next year, but now says that if the three-dose study proves suc­cess­ful, Pfiz­er and BioN­Tech ex­pect to sub­mit da­ta to reg­u­la­tors to sup­port an EUA “in the first half of 2022.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER